Latest News and Press Releases

NEW YORK, May 07, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX, “Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial...

Progenics Board Deeply Committed to Enhancing Value for all Shareholders Repeated Efforts to Engage Meaningfully with Velan Rebuffed No Shareholder Action Required at this Time NEW YORK, May 06,...

-Phase 2/3 OSPREY Data Demonstrates PyL’s High Specificity and Sensitivity in Detecting Prostate Cancer- -Data Generated Under PyL Research Access Program Supports Potential of PyL to Detect Disease...

NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...

NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find,...

NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight...

NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight...

AZEDRA® (iobenguane I 131) U.S. Commercial Launch – 14 Treatment Requests from Patients Have Been Received and Scheduling for those Patients is Underway; 8 Centers Throughout the U.S. are Ready to...

NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company focused on the development and commercialization of innovative targeted medicines and...

NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...